Search results
Showing 31 to 45 of 50 results for bortezomib
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Evidence-based recommendations on ixazomib with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.
Multiple myeloma - bortezomib (consolidation therapy) [ID529]
Discontinued Reference number: GID-TAG320
Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]
Discontinued Reference number: GID-TAG425
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]
Discontinued Reference number: GID-TAG435
Discontinued Reference number: GID-TA10171
Discontinued Reference number: GID-TA10502
cell transplantation. These studies were performed before thalidomide, bortezomib and lenalidomide were used as myeloma treatments.These...
Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.
In development Reference number: GID-TA10568 Expected publication date: TBC
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA573)
This guidance has been updated and replaced by NICE technology appraisal guidance 897.
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.